Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Relatively low concentrations of COTI-2 are active against all human glioblastoma cell lines tested (U87-MG
PubMed Central PMCID: PMC2683762
Astrid S Clarke
6-trihydroxy-2-methyl-9
InChiKey: QMNWXHSYPXQFSK-XCUBXKJBSA-N
Dihydroergotamine mesylate Catalog No.:M19056-C Relatively low concentrations of COTI-2Dihydroergotamine mesylate is an ergot alkaloid used to treat migraines. Target: 5 HT ReceptorsDihydroergotamine is not as effective as sumatriptan or phenothiazines as a single agent for treatment of acute migraine headache; however, when administered with an antiemetic, dihydroergotamine appears to be as effective as opiates, ketorolac, or valproate. Given its nonnarcotic properties, parenteral dihydroergotamine combined with an antiemetic should be